ARLINGTON, Va.–(BUSINESS WIRE)–The Medical Device Innovation Consortium (MDIC) today announced that Andrew Fish, JD has been appointed as President and Chief Executive Officer, effective July 20, 2022. Mr. Fish succeeds Pamela Goldberg who is stepping down after leading the organization for four years.
Mr. Fish joins MDIC following his most recent tenure as Executive Director, Center for Digital Health and Head of Sector Initiatives at AdvaMed, where he significantly expanded the association’s digital health membership and scope of work while supporting the Center’s Executive Leadership Group. Previously, Mr. Fish served as the first Executive Director of AdvaMedDx, AdvaMed’s corporate division focused on in vitro diagnostics, and subsequently as AdvaMed’s Chief Strategy Officer, overseeing the association’s global and domestic policy departments and providing thought leadership on the fast-evolving role of medical technology across all care delivery settings. Mr. Fish has demonstrated consistent success in developing effective public policies and achieving advocacy goals in numerous areas of healthcare regulation and delivery.
“Over the past several months the Board conducted an extensive search for a CEO with substantial experience in building and leading cross-sectional teams and a passion for medical device innovation. With his exceptional track record of leading and growing organizations with a commitment to advancing innovative patient care, Andrew is the ideal leader for MDIC as we continue to collaborate with our partners to advance science and enable transformational medical technology to shape the future,” said MDIC Board Chairman Jijo James MD, Chief Medical Officer, MedTech and External Innovation at Johnson & Johnson.
“CDRH congratulates Andy Fish on his appointment as the new President and CEO of MDIC. We look forward to working with Andy and our continued collaboration and partnership with MDIC to support medical device safety and innovation in the interest of patient health,” said Jeffrey Shuren MD, JD, Director, Center for Devices and Radiological Health (CDRH), FDA.
MDIC, through its public-private partnership among government and regulatory agencies, nonprofits, and the medical device industry, aims to advance regulatory science and bring innovative technologies to patients. MDIC coordinates the development of methods, tools, and resources used in managing the medical device lifecycle to improve patient access to cutting-edge medical technology.
“Bringing more than 20 years of experience in the industry, Andrew has the knowledge, expertise, and commitment to continue to build on MDIC’s success that Pamela Goldberg helped to establish. Among other accomplishments, Pamela helped to launch of the Health Economics and Patient Value initiative to increase the utilization of real-world evidence in healthcare decision making. We are grateful for her leadership over the past four years,” said James.
“Andy’s service at AdvaMed over the past 12 years has prepared him very well to lead MDIC,” said AdvaMed President and CEO Scott Whitaker. “While we will miss Andy, we’re glad to know he’s not going too far—MDIC has always been a great partner of AdvaMed’s, given our shared mission to improve patient care, and we look forward to continuing that good work with MDIC under his leadership.”
In accepting the position as Chief Executive Officer, Mr. Fish said, “I am grateful for the opportunity to lead MDIC by serving as President and CEO. I look forward to bringing together medical devices and diagnostics stakeholders and leveraging our collective expertise, resources, and data to create new methods, tools, approaches, and standards that will assist in developing safe and effective medical technologies for patients everywhere.”
About the Medical Device Innovation Consortium
Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product lifecycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market. For more information, visit http://www.mdic.org.
Gregory Bologna, MDIC
AVP, Marketing and Communications